Eisai Co. Ltd. Projects Substantial Growth in Leqembi Sales for Fiscal 2026
Eisai Co. Ltd., a leading Japanese pharmaceutical company, has announced that sales of its Alzheimer’s disease therapy Leqembi (lecanemab) are projected to reach ¥143.5 billion for the fiscal year 2026 (April 2026 – March 2027). This figure represents an increase of approximately two‑thirds relative to the previous fiscal year’s volume. In addition, the company expects to generate about SEK 880 million in royalty income for its partner, BioArctic.
Commercial Trajectory and Regulatory Context
Leqembi has received regulatory approvals in more than fifty countries, underscoring its broad international acceptance. The company is currently undergoing regulatory review in several additional markets, which is expected to further expand its commercial footprint. The projected sales figure reflects sustained momentum following the drug’s launch and aligns with the company’s strategic focus on expanding its Alzheimer’s portfolio.
Financial Performance Highlights
| Metric | FY 2025 (Actual) | FY 2026 (Guided) | Change |
|---|---|---|---|
| Revenue | ↑ a few percent | Targeted growth of ~7 % | Positive trend |
| Profit Before Tax | ↓ ≈ 1/6 | Not disclosed | Decline |
| Operating Profit | ↓ | Not disclosed | Decline |
| Attributable Profit | Forecasted increase of 35 % | Projected improvement | Strong upside |
Eisai’s earnings report indicates that while profit before tax and operating profit experienced a modest decline in FY 2025, the company remains on track to deliver a 35 % improvement in attributable profit for FY 2026. Revenue growth is projected to reach around 7 %, with Leqembi sales momentum expected to contribute materially to this upside.
Analyst Perspectives
Analysts have reacted positively to the updated forecasts, raising their target prices and maintaining an optimistic long‑term outlook for Eisai. The Leqembi performance is viewed as a key driver of future profitability, while the partnership with BioArctic offers a structured royalty stream that is anticipated to support sustained cash flow generation. Market participants interpret the updated projections as an indication of healthy growth prospects for Eisai, though they also note the company’s sensitivity to regulatory developments and competitive dynamics within the Alzheimer’s treatment space.
Implications for Healthcare Systems
The projected increase in Leqembi sales underscores the therapy’s growing role in Alzheimer’s disease management. From a clinical perspective, the drug’s efficacy data—demonstrating a reduction in amyloid plaques and a slowing of cognitive decline—continue to support its use in early-stage Alzheimer’s patients. Safety profiles remain consistent with clinical trial observations, with the most common adverse events being infusion‑related reactions and mild to moderate systemic side effects.
For healthcare providers, the expanding market for Leqembi may translate into increased availability of a disease‑modifying therapy, potentially altering treatment algorithms and care pathways. Payers and policy makers should consider the drug’s cost‑effectiveness, particularly given the projected royalty structure that may influence pricing strategies and reimbursement decisions.
Conclusion
Eisai’s forecast for FY 2026 signals robust commercial traction for Leqembi, reinforcing the company’s position as a significant player in the Alzheimer’s therapeutic landscape. The integration of strong regulatory approvals, a predictable royalty stream from BioArctic, and an anticipated improvement in attributable profitability collectively suggest a favorable trajectory for Eisai, contingent upon continued regulatory support and competitive positioning.
